Articles by Paul Raeburn

At the same time a Canadian government chemist is appealing his dismissal over the nature of his criticism of a breast implant device (see story on page 7), a U.S. Geological Survey scientist in Menlo Park, Calif., who took a stand on a local environmental dispute faces a 28-day suspension. The geological survey says that geologist Howard Wilshire violated its guidelines by allowing an environmental activist to accompany him on a survey. The controversy began in February when Wilshire, a 30

Monsanto Co. and the Soviet Union have brought glasnost to the lab with a three-year agreement to establish a joint laboratory at the modem Shemyakin Institute of Bio-organic Chemistry in Moscow. The agreement marks the first time that a bio- technology company has launched a major collaboration with the Soviet Union. The laboratory will be staffed by 10 to 15 Soviet scientists now being recruited from other laboratories at Shemyakin, and supported by Monsanto with a contribution of $300,00

FRANKLIN, TENN.—Three years ago, when an oncologist named Robert Oldham created a company called Biotherapeutics, some called it genius; some called it downright unethical; still others called it capitalism in its most predatory form. But everyone acknowledged that the concept bad the potential to change the face of cancer therapy. Oldham, former head of the National Cancer Institute’s biological therapy program, proposed to offer experimental treatments to any cancer patient w

First ‘superchemist’ Ed Engler threw corporate hierarchy to the winds, then IBM promoted him for it None of his IBM colleagues would have ever guessed that Edward Engler was about to turn his career upside-down on that February day in 1987. But looking back on it, the signs were there. Everyone knew this about Engler: The 39-year-old chemist was moving smartly along Big Blue’s management track. Already a second-tier manager, he had four laboratory directors reporting to hi